发明名称 New N-benzylindolyl glyoxylic acid derivatives are useful as antitumor agents
摘要 N-benzylindol-3-yl glyoxylic acid derivatives (I) or their acid addition salts, are new. N-benzylindol-3-yl glyoxylic acid derivatives of formula (I), or their acid addition salts, are new. R = nitro or amino is optionally substituted by amino is substituted by 1 or 2 1-6C alkyl or cycloalkyl; 1-6C acyl; phenyl(1-6C)alkyl; (hetero)aroyl; 1-6C alkylsulfonyl; arylsulfonyl; Z; Boc; 9-fluorenylmethoxycarbonyl; triphenyl; 2-(4-pyridyl)ethoxycarbonyl; diphenylmethylsilyl; or it is maleimido, succinimido or phthalimido; also, when R1 = hydrogen, Me, benzyl, Z, Boc or acetyl, R may be N-linked Gly, Ala, Leu, Ile, Ser, Phe, His, Arg, Lys, Asn or Glu. In R1, substituents on alkyl are phenyl (optionally substituted by one or more halo, 1-6C alkyl, 3-7C cycloalkyl, carboxy, 1-6C alkoxycarbonyl, trifluoromethyl, hydroxy, MeO, EtO, benzyloxy) or benzyl (optionally ring substituted by one or more 1-6C alkyl, halo or trifluoromethyl); R1 = H, 1-6C alkyl (optionally substituted), benzyloxycarbonyl (Z), tert-butoxycarbonyl (Boc) or acetyl; R2 = phenyl (optionally substituted by one or more 1-6C alkyl or alkoxy, CN, halo, trifluoromethyl, hydroxy, benzyloxy, nitro, amino (optionally substituted by 1-6C alkyl or alkoxycarbonyl), carboxy or 1-6C alkoxycarbonyl; substituents for 2-pyrimidinyl are one or more Me; those for quinolinyl are one or more of 1-6C alkyl, halo, nitro, amino or 1-6C alkylamino, and ring carbons in the pyridylmethyl component of quinolyl and quinolylmethyl may be substituted by 1-6C alkyl, alkoxy or alkoxycarbonylamino, nitro or amino), pyridinyl (optionally substituted by R5 and R6, optionally as N-oxide), or (all optionally substituted) 2- or 4-pyrimidinyl, quinolinyl, 3- or 4-quinolinylmethyl, also allylaminocarbonyl-2-methylprop-1-yl, or a wide variety of other substituents, depending on nature of R1, or R1 and R2 together complete 4-R7-piperazino or homopiperazino. When R1 = H, Me, benzyl, Z, Boc or acetyl, R2 may be N-linked Gly, Ala, Leu, Ile, Ser, Phe, His, Arg, Lys, Asn or Glu, or the residue of any natural or non-natural amino acid (optionally protected), and if R2 = residue of Asp or Glu, the second, non-bound carboxy may be as free acid or 1-6C alkyl ester; R5, R6 = 1-6C alkyl or alkoxy, 3-7C cycloalkyl, nitro, amino, hydroxy, halo, trifluoromethyl, ethoxycarbonylamino or carboxy(1-4C)alkoxy; R7 = alkyl, phenyl (optionally substituted by one or more 1-6C alkyl or alkoxy, halo, nitro, amino or 1-6C alkylamino), benzhydryl or bis-p-fluorobenzhydryl; R3, R4 = H, 1-6C alkyl, alkoxy or alkanoyl, 3-7C cycloalkyl, halo, benzyloxy, nitro, amino (optionally substituted by 1 or 2 1-4C alkyl), 1-6C alkoxycarbonylamino or 1-6C alkoxycarbonylamino(1-6C) alkyl; and Z = O or S. Independent claims are also included for: (a) pharmaceutical composition comprising (I) or its salt, optionally also carriers, diluents and/or auxiliaries; and (b) galenical formulations comprising (I) or its salt as (coated) tablets, solutions for infusion, capsules, ampoules, suppositories, plasters, inhalable powders, suspensions, creams or ointments.
申请公布号 DE19962300(A1) 申请公布日期 2001.06.28
申请号 DE19991062300 申请日期 1999.12.23
申请人 ASTA MEDICA AG 发明人 GUENTHER, ECKHARD;EMIG, PETER;REICHERT, DIETMAR;LE BAUT, GUILLAUME;NICKEL, BERND;BACHER, GERALD
分类号 C07D209/22;A61K9/02;A61K9/06;A61K9/08;A61K9/10;A61K9/12;A61K9/20;A61K9/48;A61K31/404;A61K31/4439;A61P35/00;C07D401/06;C07D401/12;(IPC1-7):C07D401/06;C07D401/14;C07D403/06;C07D403/14;A61K31/40 主分类号 C07D209/22
代理机构 代理人
主权项
地址